Recent investigations have converged on the convergence of GLP|GIP|GCGR stimulant therapies and DA communication. While GIP stimulators are widely employed for managing type 2 diabetes, their unexpected consequences on motivation circuits, specifically mediated by dopamine pathways, are gaining s